CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it was added to the Russell 3000(R) Index as well as the Russell Microcap(R) Index when Russell Investment Group reconstituted its family of U.S. indexes on June 22, 2007.
